APS Share Price

Open 7.56 Change Price %
High 7.86 1 Day 0.00 0.00
Low 7.56 1 Week 0.00 0.00
Close 7.86 1 Month 0.00 0.00
Volume 1020 1 Year 0.00 0.00
52 Week High 2.79
52 Week Low 1.16
APS Important Levels
Resistance 2 8.14
Resistance 1 8.02
Pivot 7.76
Support 1 7.70
Support 2 7.58
ETR Germany Most Active Stocks
CBK 6.59 -1.93%
CBK 6.59 -1.93%
DBK 14.84 -1.92%
DBK 14.84 -1.92%
DTE 14.73 0.55%
DTE 14.73 0.55%
DTE 14.73 0.55%
DTE 14.73 0.55%
DTE 14.73 0.55%
EOAN 6.07 -0.33%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
PC6A 72.70 17.26%
5M71 39.00 13.70%
FMV 9.12 11.63%
PA2 16.55 7.54%
BEO 3.38 6.96%
ITN 0.48 6.67%
G6P 3.20 6.31%
T5O 8.80 6.02%
CRZ 1.45 5.84%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
CEW3 0.18 -18.18%
SYZ 10.25 -12.39%
SYZ 10.25 -12.39%
USE 0.22 -8.33%
TIN 0.56 -8.20%
More..

ARIAD Pharmaceuticals Inc (ETR: APS)

APS Technical Analysis 3
As on 18th May 2015 APS Share Price closed @ 7.86 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.91 & Buy for SHORT-TERM with Stoploss of 7.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
APS Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
APS Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ariad.com
APS Address
APS
26 Landsdowne Street
Cambridge, MA 02139
United States
Phone: 617-494-0400
Fax: 617-494-8144
APS Latest News
Interactive Technical Analysis Chart ARIAD Pharmaceuticals Inc ( APS ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ARIAD Pharmaceuticals Inc
APS Business Profile
ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.